GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...
Medpage Today on MSN2d
Which High-Risk Patients Should Get the RSV Vaccine?The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...
Image by Arek Socha from Pixabay November 12, 2024 - By Lorna Fernandes - As fall arrives, so does respiratory syncytial ...
Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.
MyChesCo on MSN1mon
GSK’s AREXVY Vaccine Shows Promising Results Across Three RSV SeasonsPHILADELPHIA, PA — GSK plc (LSE/NYSE: GSK) has released new data from the AReSVi-006 Phase III trial, demonstrating the ...
However, even established players have struggled. In its Q3 results, GSK (GSK), the first to receive U.S. approval for an RSV ...
Mississauga: GSK's AREXVY (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada ...
The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...
Medpage Today on MSN2d
Real-World Data on the RSV Vaccine for Older AdultsRegarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...
GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while specialty medicines ...
GlobalData on MSN7d
GSK’s RSV vaccine approved in Canada for adults aged 50 to 59GSK has received approval for its vaccine, AREXVY, in Canada to prevent LRTD caused by RSV in adults aged 50 to 59 years.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback